Galapagos

GLPG NASDAQ
183.40
+9.39
+5.40%
Closed 16:00 07/19 EDT
Open
185.13
Prev Close
174.01
High
186.74
Low
180.74
Volume
723.58K
Avg Vol (3M)
150.52K
52 Week High
186.74
52 Week Low
85.00
% Turnover
1.32%
Market Cap
10.02B
1D
5D
1M
3M
1Y
5Y

Company Profile

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
MORE >

Recently

Name
Price
%Change